Large case-control study indicates no association of KIR genotype and risk of developing acute myeloid leukemia

Publikation: Beitrag in FachzeitschriftForschungsartikelBeigetragenBegutachtung

Beitragende

  • Falk Heidenreich - , Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus Dresden, DKMS Clinical Trials Unit gGmbH (Autor:in)
  • Bose Falk - , DKMS Clinical Trials Unit gGmbH (Autor:in)
  • Henning Baldauf - , DKMS Clinical Trials Unit gGmbH (Autor:in)
  • Carolin Massalski - , DKMS Life Science Lab gGmbH (Autor:in)
  • Gesine Schäfer - , DKMS Life Science Lab gGmbH (Autor:in)
  • Elke Rücker-Braun - , Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus Dresden, DKMS Clinical Trials Unit gGmbH (Autor:in)
  • Heidi Altmann - , Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus Dresden (Autor:in)
  • Jürgen Sauter - , DKMS Donor Center gGmbH (Autor:in)
  • Ute V. Solloch - , DKMS Donor Center gGmbH (Autor:in)
  • Vinzenz Lange - , DKMS Life Science Lab gGmbH (Autor:in)
  • Friedrich Stölzel - , Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus Dresden (Autor:in)
  • Christoph Röllig - , Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus Dresden (Autor:in)
  • Jan M. Middeke - , Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus Dresden (Autor:in)
  • Malte von Bonin - , Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus Dresden (Autor:in)
  • Christian Thiede - , Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus Dresden (Autor:in)
  • Kerstin Schäfer-Eckart - , Klinikum Nurnberg (Autor:in)
  • Carsten Müller-Tidow - , Universität Heidelberg (Autor:in)
  • Stefan W. Krause - , Friedrich-Alexander-Universität Erlangen-Nürnberg (Autor:in)
  • Sabrina Kraus - , Julius-Maximilians-Universität Würzburg (Autor:in)
  • Martin Kaufmann - , Robert Bosch Krankenhaus Stuttgart (Autor:in)
  • Mathias Hänel - , Klinikum Chemnitz gGmbH (Autor:in)
  • Hubert Serve - , Universitätsklinikum Frankfurt (Autor:in)
  • Andreas Neubauer - , Philipps-Universität Marburg (Autor:in)
  • Martin Bornhäuser - , Medizinische Klinik und Poliklinik I, Universitäts KrebsCentrum Dresden (Autor:in)
  • Alexander H. Schmidt - , DKMS Clinical Trials Unit gGmbH, DKMS Donor Center gGmbH (Autor:in)
  • Johannes Schetelig - , Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus Dresden, DKMS Clinical Trials Unit gGmbH (Autor:in)

Abstract

Immunogenetic association studies may give rise to new hypotheses on the immune surveillance of cancer. We hypothesized that certain combinations of killer immunoglobulin-like receptor (KIR) and HLA genotypes may enhance natural killer (NK) cell immunity against nascent acute myeloid leukemia (AML) and, thereby, lead to a skewed genotype distribution among patients. For this purpose, we analyzed KIR and HLA genotypes of 1767 German patients with AML and compared the results with that of the data of 51 890 German volunteers who had registered with German bone marrow donor file (DKMS). Patient samples were retrieved from the Collaborative Biobank and the biorepository of the Study Alliance Leukemia. All samples were genotyped with high-resolution amplicon-based next-generation sequencing. Because of the large number of controls, this study was very sensitive to detect the impact of KIR genotype. Knowledge on KIRs and their cognate HLA ligands allowed for testing of several hypotheses of NK cell–mediated endogenous leukemia surveillance. We did not find significant differences between the 2 cohorts in regard to the presence or absence of single KIR genes. When grouped based on telomeric or centromeric gene content, the major haplotypes A/A, A/B, and B/B were equally distributed among patients and control subjects. Using information on KIRs and their HLA ligands, we further tested receptor-ligand models and summation models without revealing markedly significant differences between patients and controls, albeit we observed a trend pointing at a minor protective effect of a low number of inhibitory KIR/KIR-ligand pairs. The results suggest that the KIR/KIR-ligand genotype has no effect on the susceptibility for the development of de novo AML.

Details

OriginalspracheEnglisch
Seiten (von - bis)2994-3004
Seitenumfang11
FachzeitschriftBlood advances
Jahrgang7
Ausgabenummer13
PublikationsstatusVeröffentlicht - 11 Juli 2023
Peer-Review-StatusJa

Externe IDs

PubMed 36689727

Schlagworte

Ziele für nachhaltige Entwicklung

ASJC Scopus Sachgebiete

Schlagwörter

  • Humans, Ligands, Genotype, Receptors, KIR/genetics, Leukemia, Myeloid, Acute/genetics, Case-Control Studies